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Abstract
Purpose There are numerous biomarkers which may have potential predictive and prognostic significance in breast cancer. 
This is extremely important in older adults, who may opt for less aggressive therapy. This work outlines the literature on 
biological assessment outside of standard biomarkers (defined as ER, PgR, HER2, Ki67) in women ≥ 65 years with primary 
operable invasive breast cancer, to determine which additional biomarkers are relevant to outcome in older women.
Methods Medline and Embase databases were searched. Studies were eligible if included ≥ 50 patients aged ≥ 65 years; 
stratified results by age; measured a biomarker outside of standard assay and reported patient data.
Results A total of 12 studies were appraised involving 5000 patients, measuring 28 biomarkers. The studies were extremely 
varied in methodology and outcome but three themes emerged: 1. Differences in biomarker expression between younger 
and older women, indicating that breast cancer in older women is generally less aggressive compared to younger women; 
2. Relationship of biomarker expression with survival, suggesting biomarkers which may exclusively predict response to 
primary treatment in older women; 3. Association of biomarker with chemotherapy, suggesting that older patients should 
not be declined chemotherapy based on age alone.
Conclusion There is evidence to support further investigation of B-cell lymphoma (BCL2), liver kinase (LK)B1, epidermal 
growth factor receptor (EGFR), cytoplasmic cyclin-E, mucin (MUC)1 and cytokeratins (CKs) as potential predictive or 
prognostic markers in older women with breast cancer undergoing surgery. Studies exploring these biomarkers in larger 
cohorts and in women undergoing non-operative therapies are required.
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 + ve  Positive
− ve  Negative
AIB  Amplified in breast cancer
ALDH  Aldehyde dehydrogenase
AR  Androgen receptor
BCL  B-cell lymphoma
BCS  Breast conserving surgery
BCSS  Breast cancer specific survival
BRCA  Breast cancer gene
CA  Conference abstract
CDH  Chromodomain helicase DNA binding protein
CEA  Carcinoembryonic antigen
CK  Cytokeratin
EGFR  Epidermal growth factor receptor
ER  Oestrogen receptor
FP  Full paper
IGF  Insulin-like growth factor
IL  Interleukin
HER  Human epidermal growth factor receptor
HRD  Homologous recombination deficiency
KMT2C  Lysine methytransferase
LK  Liver kinase
MAP2K  Mitogen-activated protein kinase




NAHT  Neoadjuvant hormonal therapy
NCOR  Nuclear receptor corepressor
NF  Normal function
PAI  Plasminogen activator inhibitor
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PgR  Progesterone receptor
PFS  Progression free survival
PTEN  Phosphatase and tensin homolog
RANTES  Regulated upon activation, normal T cell 
expressions and presumably secreted
RS  Recurrence score
RUNX  Runt-related transcription factor
TNF  Tumour necrosis factor
TP  Translocator protein
TP53  Tumour suppressor gene p53
TYPMS  Thymidine phosphorylase
U  Unknown
VEGF  Vascular endothelial growth factor
Introduction
The number of women aged ≥ 65 years living with breast 
cancer worldwide will quadruple by 2040 [1, 2]. Despite 
this, there are few guidelines for management of breast 
cancer specific to older women. The older population have 
unique geriatric issues, which may impact their decision 
making process when considering treatment options, for 
example, comorbidity, fitness for surgery, level of social 
activity3. Furthermore, curative treatment alone may not be 
the goal in mind for older women; quality of life and preser-
vation of function may be more important [4].
Traditionally, the biomarkers oestrogen receptor (ER), 
progesterone receptor (PR), human epidermal growth fac-
tor receptor (HER)2 and more recently, Ki67 have been 
measured in routine clinical practice. Over time the study of 
breast cancer has revealed it’s heterogeneous nature, with a 
spectrum of many subtypes with distinct biological features 
[5]. This is even more pertinent in the older patient; the older 
population generally exhibit less aggressive features regard-
less of subtype [6–9].
Therefore, treatment plans based on routinely meas-
ured biomarkers and our current understanding of disease 
subtypes may no longer be adequate for older women. 
For example, even within the group of patients who have 
tumours which are ER-positive, outcome differs depending 
on degree of ER-positivity [7]. Due to competing causes of 
death, it is hypothesised that there are a group of patients 
who may never face mortality from the disease [10].
Current predictive and prognostic tools available on the 
market for example Oncotype DX [11], a genomic test and 
Adjuvant! Online [12], which uses standard clinico-patho-
logical features, are focussed towards adjuvant rather than 
primary treatment and recruitment of older women in their 
conception is lacking [13]. These existing tools were devel-
oped from patients undergoing primary surgery following 
which they were used to determine prognosis and as such, 
potential benefit from adjuvant therapies. There is a need 
for prognostic tools unique to older women with operable 
invasive breast cancer, who might not necessarily receive 
primary surgery.
The aim of this work is to review the evidence base for 
biological markers outside of those routinely measured in 
clinical practice and avenues for future research.
Materials and methods
A review protocol was developed based on the Preferred 
Reporting Items for Systematic Review and Meta-Analysis 
(PRISMA) statement [14] and using the support of a Senior 
Research Librarian from the University of Nottingham.
Search strategy
The Medline and Embase databases were searched using 
OVID interface on the 25th January 2021. The importance 
of the unique biology of breast cancer in older women has 
become more understood in the last decade therefore, the 
search was limited to studies published within the past 
10 years. Studies were restricted to those published in Eng-
lish language and with full-text available.
Titles and abstracts were searched using the following 
terms: (breast cancer) AND (older OR elderly OR geriatric 
OR aged) AND (primary OR operable OR non-metastatic 
OR surgery) AND (biology OR biomarker(s) OR marker(s) 
or subtype). Duplicate publications were excluded.
Articles were screened by two independent researchers 
(RP and LA) in two stages: screening of titles and abstracts 
followed by the retrieval and screening of full-text articles. 
Discrepancies were resolved by discussion.
Inclusion criteria were as follows:
• Female participants only,
• Inclusion of at least 50 female participants ≥ 65 years of 
age with primary operable invasive breast cancer,
• Stratification of results by age,
• Measurement of biomarker outside of standard assay 
(standard assay defined as ER, PgR), HER2 and Ki67; 
luminal A, luminal B, basal or triple negative, HER2-
enriched, or synonymous descriptions) on breast tissue 
sample,
• Full-text articles only.
Studies were excluded if:
• Biology or breast cancer not discussed,
• Restricted access to study report/data/full-text,
• Review article, letter to the editor, editorial report, case 
report, conference abstract,




All data were extracted directly from the study text. When 
available, the following variables were extracted: year of 
publication; country; definition of older women; number 
of women ≥ 65 years with primary invasive breast cancer 
included; type of breast cancer and treatment; tumour sub-
type if known; summary of how biomarker(s) measured; 
key findings.
Critical appraisal
Methodological quality of papers was assessed using the 
Reporting Recommendations for Tumour Marker Prognos-
tic Studies (REMARK) criteria [15] and in accordance 
with the PRISMA statement [14]. Since the included stud-
ies were extremely varied in methodology and context, 
meta-analysis was not performed.
Results
Details of the literature search and study selection are 
shown in Fig. 1. Selected studies are referred to by the 
number allocated in Tables 1 and 2.
Summary
Twelve studies met the inclusion criteria and were 
included in this paper. These studies included a total of 
5000 women aged ≥ 65 years with primary operable inva-
sive breast cancer. All of the studies were observational 
with the exception of Study #10 and #11 which were 
case–control studies.
Reporting standard
The results of REMARK assessment of full-text papers 
are given in Supplementary File 1. All papers achieved at 
least 75% of the REMARK criteria for reporting of a study 
including a biomarker. The most frequently missed criteria 
were number nine in relation to rationale of sample size 
(only two out of twelve studies included this) and 16 and 
17 in the reporting of multivariate analyses and confidence 
intervals (only four and five studies included this informa-
tion, respectively.
General characteristics of the studies
The 12 studies included patients with primary breast can-
cer with a range of pathology. Details of tumour stage, 
grade, hormone receptor status and histological type where 
reported, are presented in Supplementary File 2.
Four studies made a direct comparison between meas-
urement of biomarkers in an older compared to a younger 
cohort (Table 1) [9, 16–19]. The remaining eight studies 
measured a biomarker in an older cohort alone (Table 2) 
[20–27].
Six of the studies were performed in the UK [9, 17, 20, 
21], four in other European countries [16, 18, 26, 27] and 
one each in China [22] and USA [25]. The number of eli-
gible patients included per study varied enormously from 
56 [25] to 1698 [27]. Eight studies defined older women 
as ≥ 70 years and five ≥ 65 years. All 12 studies examined 
patients treated by primary surgery with two of those also 
including those treated by non-operative therapies [20, 21].
A total of 28 biomarkers were measured in the 12 stud-
ies. The most frequently measured biomarkers outside of 
standard assay (as defined in the methodology) were tumour 
protein (p53), CKs, MUC1 and BCL2, each measured in 
four studies. Interleukin (IL)6, insulin growth factor (IGF)1, 
LKB1 and EGFR were measured in three studies. Regu-
lated upon activation normal T cell expressed and presum-
ably secreted (RANTES), monocyte chemotactic protein 
(MCP)1, phosphatase and tensin homolog (PTEN), ampli-
fied in breast cancer (AIB1), HER3, HER4, breast cancer 
gene (BRCA)1, vascular endothelial growth factor (VEGF) 
and e-cadherin appeared in two studies. The following bio-
markers appears in one study each: IL10, PIK3CA, leu-
cocyte telomere length (LTL), translocator protein (TP), 
cytoplasmic cyclin-E, d-dimer, albumin, IGF binding pro-
tein (BP)3, tumour necrosis factor (TNF)-alpha, vitamin D, 
alcohol dehydrogenase (ALDH)1. Only four studies (33%) 
gave a breakdown of tumours by classical subtypes.
Biomarker expression was based on tissue samples in 
eight studies; six on surgical excision (SE) specimen and 
two core needle biopsy (CNB). Four studies used peripheral 
blood samples.
Significant findings
The following themes emerged: differences between older 
and younger women; relationship of biomarker with sur-
vival; association of biomarker with chemotherapy use.
Direct comparison of younger to older cohort
There was higher expression of IL6 [16], MCP1 [16], BCL2 
[9], luminal cytokeratins [9, 20, 21], MUC1 [17], BRCA1 
[17], BRCA2 [17], CEA [19] and CA 15-3 [19] in older 





























Addional records idenfied 
through other sources 
(n = 1)
Records aer duplicates removed 
(n = 762) 
Records screened 
(n = 762) 
Records excluded 
(n = 611) 
Full-text arcles assessed 
for eligibility 
(n = 151)
Full-text arcles excluded, with reasons
(n = 139) 
No indicaon of how many women ≥65 involved 
(n=51) 
No analysis by age (n=35) 
No biomarker outside of standard assay 
described (n=25) 
Conference abstract only (n=9) 
Review arcle (n=5) 
Trial outline only (n=3) 
Less than 50 parcipants (n=3)  
Non-invasive only (n=2) 
Only younger women (n=2) 
Male paents only (n=1) 
Access to full-text restricted (n=1) 
Mulple cancer sites analysed (n=1) 
Metastac cancer only (n=1) 
Studies included in 
qualitave synthesis 
(n = 12)













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Lower levels of IGF1 [16], Ki67 [9], basal cytokeratins 
[17], p53 [17], EGFR [17] and ALDH1 [18] were seen in 
older women.
Relationship of biomarker with survival
The significant findings in relation to this theme are now 
summarised.
Study #3 identified a novel biological cluster (low ER 
luminal) present in older women undergoing surgery, which 
was not seen in younger women. The presence of this clus-
ter was confirmed in core needle biopsy samples of older 
women in study #6. The low ER luminal cluster had a dis-
tinct biological pattern and had lower BCSS compared to 
luminal A and B type tumours.
A better BCSS was associated with low expression of 
MUC1 [21] and cytoplasmic cyclin-E [23] and high expres-
sion of EGFR [9].
High expression of BCL2 and low expression of LKB1 
were associated with longer time to progression of disease in 
patients receiving primary endocrine therapy (PET) in study 
#5. Conversely in study #9, high expression of LKB1 was 
associated with better BCSS in patients receiving adjuvant 
endocrine therapy.
Expression of TP was associated with increased stage and 
grade of tumour at presentation in study #7. IL6 was associ-
ated with measures of clinical frailty [16].
Associations of biomarker with chemotherapy use
Despite not having received adjuvant chemotherapy, there 
was no difference in clinical outcome of older women with 
TNBC in study #2, compared to a series of younger women 
who did receive chemotherapy.
Study #10 found no difference in expression of biomark-
ers representing inflammation and frailty, in patients who 
completed chemotherapy compared to those who did not 
which was confirmed in study #11 which examined biomark-
ers of ageing and frailty.
Discussion
The studies in this review add to the growing body of evi-
dence that breast cancer in older women is less aggressive 
when compared to younger women and therefore, treat-
ments offered should be tailored, instead of blanket treat-
ment policies.
Reporting standard
All papers achieved at least 75% of the REMARK criteria 
which is an acceptable rate. Many studies did not present 







































































































































































































































































































































































































































































































































































The main problem with studies of this kind is recruit-
ment of many older women to these trials. Recruitment of 
older women to clinical studies is lacking due to bias by the 
clinician or patient, concerns regarding side effects of treat-
ment and competing comorbidities. Therefore, a prescribed 
sample size may not be an appropriate goal in studies of 
older women, but simply to recruit as many participants as 
possible.
Differences between older and younger women
IL6 and MCP1 are markers of ageing, therefore their 
increased expression in older women is anticipated as well 
as lower levels of IGF1, a marker of oxidative stress.
Higher expression of BRCA1 and 2 in older women could 
be explained by longer time to accumulate damage to these 
genes.
Many of our findings agree with the literature that breast 
cancer in older women generally displays less aggressive 
features for example, low expression of Ki67 (a marker of 
proliferation), ALDH (a breast cancer stem cell), EGFR (a 
growth factor receptor related to HER2) and p53 (a gene 
which promotes tumorigenesis) and high expression of 
BCL2 (an anti-apoptosis marker).
Contrary to this, are our findings related to MUC1 and 
cytokeratins.
MUC1 is an epithelial cell surface protein that is overex-
pressed in over 90% of breast as well as other cancers [28]. 
Evidence in breast cancers in younger women, show that 
high levels are associated with poor clinical outcome [29, 
30]. We would therefore expect lower levels of MUC1 in 
older women, if they have less aggressive tumours.
In normal breast tissue, CK 5, CK14 and CK17 are 
expressed in myoepithelial cells and CK7, CK8, CK18, 
CK19, CK20 in ductal epithelium [31]. The role of expres-
sion of cytokeratins in breast cancer remains unclear. For 
example, high levels of CK18 have been shown to be associ-
ated with worse survival [32] as have CK17 and CK 5/6 [33]. 
A literature review by Haupt et al. [34] looked at the litera-
ture relating to basal-like breast carcinomas and confirmed 
that expression of basal CKs was an independent prognos-
tic factor in lymph node negative cases, but in lymph node 
positive cases this was unclear. Overall, the evidence was 
suggestive that basal-like breast carcinomas are associated 
with worse clinical outcome. The contradictory results from 
this present literature review are certainly worthy of further 
investigation.
Relationship of biomarker with survival
The novel biological cluster identified in study #3 and #6 
(low ER luminal) had a distinct biological pattern and had 
lower breast cancer specific survival (BCSS) compared to 
luminal A and B type tumours. Low ER luminal had higher 
expression of CK7/8, BRCA1 and BCL-2, and lower expres-
sion of ER compared to Luminal A and B. Although the low 
ER luminal cluster has lower BCSS compared to luminal 
A and B response to surgery or PET within this cluster is 
similar. This could be interpreted as both treatments being 
equally as effective in this cluster, or that both treatments are 
equally unsatisfactory to treat this group of patients. This is 
an interesting finding and may suggest that in addition to 
conventional features such as grade, nodal status and ER 
status, cytokeratin expression may be significant in the role 
of response to PET.
A better BCSS was associated with low expression of 
MUC1 [21] and cytoplasmic cyclin-E [23] and high expres-
sion of EGFR [9].
Interestingly, in study #8, cytoplasmic cyclin E was the 
only independent biomarker of BCSS alongside a large panel 
of other biomarkers including EGFR There is a growing 
body of evidence to support its oncogenic role in various 
cancer types [35, 36]. Study #8 showed that at 10 years, 
42% of older patients with cytoplasmic cyclin E-positive 
tumours had died of breast cancer versus 8% of negative 
cases (p < 0.0005). They concluded that older women with 
cytoplasmic cyclin E-negative tumours are unlikely to ever 
die of breast cancer. This information could significantly 
change the focus of primary treatment for breast cancer in 
older women, especially in comorbid patients.
Specifically in older women with TNBC in study #2 [9], 
EGFR has been shown to be more common in younger com-
pared to older women. High expression of EGFR is known 
to correlate with poor clinical outcome in breast cancer [37]. 
There are now EGFR inhibitors on the market developed 
for use in other cancer types including lung and pancreatic 
cancer [28]. For breast cancer, EGFR inhibitors have not 
yet been successful in universally producing good response 
rates [38, 39].
High expression of BCL2 and low expression of LKB1 
were associated with longer time to progression of disease in 
study #5. Conversely, in study #9 high expression of LKB1 
was associated with better BCSS in patients-receiving adju-
vant endocrine therapy, but not those undergoing surgery 
alone. Other studies to date examining LKB1 in are mainly 
cell line studies [40, 41]. LKB1 could be a potential thera-
peutic target.
BCL2 was found in higher proportions in breast cancers 
of older women in study numbers #2 and #3. BCL2 regulates 
cell death by either inhibiting or inducing apoptosis, there-
fore, positivity is associated with improved outcomes. This 
agrees with findings from a large biological characterisation 
study in 2003 by Daidone et al. [42] of over 14,000 primary 
breast cancers.
Expression of TP, a marker of inflammation, was 
associated with increased stage and grade of tumour in 
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postoperative patients only; levels were undetectable pre-
operatively [22]. Therefore, it is difficult to elicit how much 
of this is due simply to the process of surgical treatment.
IL6 was associated with chronological age as well as with 
measures of clinical frailty [16] as per the Balducci score. 
The authors suggested that IL6 could be used as a predic-
tive marker to determine the toxicity of certain breast cancer 
treatments and may be a precursor to full geriatric assess-
ment, a strategy that is recommended in the field of geriatric 
oncology [43].
Associations of biomarker with chemotherapy use
In study #11 older women after surgery were assigned to 
either chemotherapy or a control group. The included bio-
markers that represent ageing suggested a minor biological 
effect in the group receiving chemotherapy, but this was not 
clinically relevant. Therefore, the authors suggested that 
older breast cancer patients should not be denied chemo-
therapy based on age. However, in study #2 of patients with 
TNBC, there was no difference in survival outcome between 
older and younger patients, despite the older patients rarely 
receiving chemotherapy.
Study #10 did not find any differences in markers of 
inflammation, oxidation or frailty amongst patients receiv-
ing chemotherapy. Lower levels of Vitamin D were reported 
in patients who were treated by chemotherapy, however, 
there was little impact on measures of functional outcome 
at 2 years’ post-diagnosis. They suggested that supplementa-
tion of Vitamin D levels by exercise and/or oral supplements 
may be useful in these patients.
Limitations
Comparability of studies is limited due to such a varied 
selection of studies with different methodology and aims. 
Although the papers described are important in their own 
merit as they contribute to the evidence based in older 
women, their heterogeneity means it is extremely difficult 
to perform a sound systematic review of the literature on this 
subject. Further work to examine each of three themes that 
emerged in this present review in more detail might be one 
way to overcome this. These themes are: comparison of biol-
ogy between younger and women; relationship of biomarker 
with survival specific to older women; relationship of bio-
marker with chemotherapy use specific to older women.
Only 4 of the 12 studies highlighted in this paper break-
down included patients by tumour subtype. Even within 
these 4 papers, the definitions of tumour subtypes varied. 
Therefore, it was not possible to draw any firm conclusions 
regarding correlation between novel biomarkers reported in 
this paper and tumour subtypes.
Studies which have included the largest number of 
patients, are retrospective in nature. One of the main hur-
dles of biological studies is availability of patient tissue 
and blood samples and long-term follow-up data, which is 
often available in retrospective datasets. With updated ethi-
cal and legal guidance regarding handling of human tissue 
and consent, new prospective studies of this kind could face 
difficulty.
The majority of studies examining patient tissue, used 
surgical excision specimens to do so. This excludes the 
important group of older women who have non-surgical 
treatment and creates potential bias towards ER-negative 
tumours (who are not suitable for PET). Therefore, results 
may not be necessarily applicable to all older women with 
breast cancer.
Four studies did not examine patient tissue but instead 
used peripheral blood sampling. The methodology behind 
tissue versus blood sampling is clearly different, as is the 
range of biomarkers that can be measured by each method. 
Due to the small number of studies included in this pre-
sent review we have considered all studies irrespective of 
sample method; however, the most significant findings have 
been found in those studies using tissue material for research 
alone.
Due to the small number of studies included in this 
review and in some of the individual studies, a small num-
ber of patients, no attempt was made to stratify patients by 
different treatments or individual pathological subgroups.
Conclusions
There is an evidence base for the importance of biomark-
ers outside those currently measured in clinical practice, 
in breast cancer in older women, compared to younger 
women. However, the range of biomarkers and methodol-
ogy used varies to such an extent it is difficult to form robust 
conclusions.
The biomarkers with the most evidence as highlighted in 
this paper which may have prognostic implications on breast 
cancer in older women include and are under reported in the 
current literature include: BCL2, cyclin E, EGFR, LKB1, 
MUC1 and CKs. Breast cancer in older women should not 
be treated the same as in their younger counterparts; there 
is a need for individualised treatment plans not purely based 
on chronological age.
Further measurement of these biomarkers using stand-
ardised methodology in larger numbers of older women will 
enable firm conclusions to be drawn about their predictive 
and prognostic value, primarily in a surgical setting. Bio-
marker assessment on a similar scale in CNB is urgently 




In the future, incorporation of these biomarkers into rou-
tine clinical practice may revolutionise the management 
of breast cancer in older women, alongside conventional 
factors.
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